(+)-JQ-1

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: Cell. 2018 Sep 20;175(1):186-199.e19. [Abstract]

Cells are treated with EPZ-6438 (1 μM) or GSK126 (1 μM) for 6 days. Protein levels are analyzed by immunoblotting. Cells are treated with EPZ-6438 (1 μM), JQ1 (0.25 μM) alone or combination for 6 days. Protein levels are analyzed by immunoblotting.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: Nat Biotechnol. 2025 Nov 6. [Abstract]

RT−PCR analysis of MYC expression in control (Ctrl, DMSO) and (+)-JQ-1-treated (JQ1, 5 μM for 24 hours) HeLa cells, normalized to the control group. JQ1 treatment suppressed MYC expression.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2019 Jan 1;79(1):251-262. [Abstract]

Cleavage of PARP is assessed by western blotting with the treatment of JQ 1.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Mar 25;16(1):2890. [Abstract]

A transwell migration assay was performed to evaluate the effect of (+)-JQ-1 (1 μM; 24 h) on TGF-β/SNAI1e-induced migration in MDA-MB-231 cells. The results showed that under both TGF-β-stimulated and unstimulated conditions, (+)-JQ-1 treatment reduced SNAI1e-induced migration in MDA-MB-231 in MCF10A-M2 cells.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: Metabolism. 2016 Oct;65(10):1478-88. [Abstract]

The BRD4 protein level in the liver is significantly suppressed by force-feeding fructose or glucose with (+)-JQ1. Protein levels of Brd4 in the liver of mice force-fed with glucose or fructose, with or without (+)-JQ1. Quantification of protein levels is performed by normalization against the level of β-actin (n = 6).

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2024 Dec 19;84(24):4808-4823.e13. [Abstract]

Ubiquitin pull-down and western blot (TPL, triptolide: 300 nM for 1 h; THZ1: 250 nM for 1 h; flavopiridol: 5 μM for 15 min; AZD4573: 500 nM for 1 h; THZ531: 500 nM for 6 h; (+)-JQ-1: 5 μM for 3 h; OA, okadaic acid: 500 nM for 1 h) all in combination with CB-5083 p97i (10 μM for 30 min).

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: Nat Chem Biol. 2024 Dec;20(12):1640-1649. [Abstract]

Western blots of BRD4 degradation in K562 cells treated with DMSO or different concentrations of (+)-JQ-1, TMX1 and GNE11 for 16 h.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2026 Jun 22;54(12):gkag631. [Abstract]

Representative GFP histograms of Jurkat cells infected with TatWT, TatLeak, or TatNull HIVGKO viruses following treatment with indicated latency-reversing agents. On 4 dpi, cells were treated overnight with 10 µM (+)-JQ-1 (JQ1).

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2022 Nov 11;41(1):321. [Abstract]

The expression of BRD4 and MYC proteins are each downregulated by JQ1 (0.5 µM; 24 h) or panobinostat (PAN; 10 nM; 24 h) alone, and more profoundly by the combination of these two inhibitors in in MB HD-MB03 and D-283 cells.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Jan 26;9(2):129. [Abstract]

The effects of treatment with the indicated epigenetic inhibitors on cleaved PARP (Clv-PARP) expression in both PC9/ER and HCC827/ER cells. β-actin is used as a loading control.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Oct 28:435:44-54. [Abstract]

H157, H1299, and HCT116 cells are harvested for preparation of whole-cell protein lysates and subsequent Western blotting to detect the indicated proteins.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Apr 28:420:195-207. [Abstract]

Shh-Light 2 cells are transfected with Gli1 or Gli2 plasmids and the expression of proteins are analyzed by Western blot. Positive control JQ1, CBC and CBD inhibit Gli1 and Gli2 overexpression induced Gli luciferase activity, GDC-0499 and GANT61 have no effects.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Apr 10:419:64-74. [Abstract]

ESCC cell lines are treated with 500 nM JQ1 for 48 h, whole cell lysates are analyzed by western blotting. The expressions of p21 and p27 are further upregulated by JQ1 concomitant with cell cycle arrest at G1 phase.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2017 Aug 28:402:100-109. [Abstract]

Expression and activation statuses of signal proteins in three BRAFV600E-mutant colon cancer cell lines treated with either RG7204, JQ1, or their combination. Phosphorylation of CRAF and AKT is suppressed by JQ1 in RKO cells and possibly in Colo205 cells (green arrow heads).

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2019 Jun:44:419-430. [Abstract]

Panc1 or MiaPaCa2 cells are exposed to JQ1 (0.5, 1, 5, or 10 μM) for 48 h, and immunoblotted for γH2AX.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: Oncogene. 2018 Aug;37(33):4611-4625. [Abstract]

ARID1A Western blot analysis of ARID1A protein levels in the ES2 polyclonal ARID1A knockout clone and ES2/OVCA429 monoclonal ARID1A knockout clones.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: Leukemia. 2017 Oct;31(10):2037-2047. [Abstract]

Immunoprecipitation with anti-BIM antibody illustrates the increased binding of BIM to BCL-2 after JQ1 treatment.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2018 Apr;10(4):e8163. [Abstract]

Western blot analysis of MYC and FGFR3 expression in lysates from MGH-U3 and RT112 cells treated with (+)-JQ1 (1 or 4 μM) for 48 h. Anti-actin antibody is used as a loading control. Pan-FGFR inhibitor, PD173074 (50 nM and 1 μM), and inactive enantiomer (-)-JQ1 (4 μM) are used as controls.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: J Med Chem. 2018 Jan 25;61(2):504-513. [Abstract]

Protein degradation profile of VHL-based BET degraders. Sub-confluent HeLa cells are treated for 24 h with varying concentration of test compounds JQ1(Compound 3), I-BET726 (Compound 4). Protein extracts are separated by SDS-PAGE and then analyzed by Western blot. Proteins Brd4, Brd3, Brd2 and β-actin are probed for JQ1and I-BET726 with specific antibodies.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2016 Jun;15(6):1217-26. [Abstract]

JQ1-mediated c-MYC repression correlates with growth inhibition. BETi preferentially inhibit c-MYC protein expression in sensitive cell lines. JQ1-sensitive GP5D, HT29 and LIM1215 cells and JQ1-resistant KM12, SW480 and HuTu80 cells where treated with JQ1 (500 nM) for 2-24 hours and c-MYC protein expression determined by western blot.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2018 Oct:156:511-523. [Abstract]

Western blot detection of the p-TEFb component CDK9, Cyclin T1 and CDK9 phosphorylation on Thr186, as well as its downstream RNA poly II CTD and phosphate CTD after J-Lat 10.6 cells are treated with PR-957 in dose-dependent manner.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: Genome Res. 2017 Nov;27(11):1830-1842. [Abstract]

Ki67 immunohistochemistry and H&E stained sections from representative xenograft per treatment arm. A marked decrease in the proliferation marker Ki67 is observed in xenografts treated with JQ1.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: Cancer Biol Ther. 2018 May 4;19(5):407-415. [Abstract]

NSCLC cells are treated with 0-8 μM JQ1 for 24h, then the whole-cell lysates are prepared and subjected to western blot assay.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: Eur J Pharm Biopharm. 2019 Jan:134:96-106. [Abstract]

Western blot analysis of p21 and G2/M regulatory molecules, cyclin B1, CDC2, p-CDC2 (Tyr-15) and CDC25A in the treatment of NL101 and BMN673.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: J Mol Cell Cardiol. 2019 Feb:127:83-96. [Abstract]

The expression of EndMT-related proteins, VE-cadherin, CD31, vimentin, α-SMA and FSP1, were compared among Ctrl, JQ1(-), JQ1, TGF-β1, and TGF-β1+JQ1 groups in both HUVECs and MAECs.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2018 Aug 1;8(1):11554. [Abstract]

A549 cells are mock-treated (0.1% DMSO in culture medium) or treated with RVX-208 at 500 nM, PFI-1 at 500 nM, JQ1 at 300 nM, or with 300 nM (-)-JQ1, an inactive enantiomer of JQ1. The cells are then infected with Ad2 at 1 PFU/cell for 24 h. Viral hexon and penton base (PB) protein is detected by immunoblotting analysis.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: PLoS Pathog. 2016 Oct 20;12(10):e1005950. [Abstract]

Dose effect of JQ1 on HSV infection. Vero cells are treated with JQ1 at concentrations as indicated. HSV-1 or HSV-2 at 1 MOI are used. The samples are used for protein expression analysis by western blot.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta. 2016 Dec;1859(12):1527-1537. [Abstract]

JQ1 treatment decreases β-catenin levels in HCT116 cells, but increases TAZ protein. When cells reach confluence, they are serum-starved overnight and pretreated with DMSO or JQ1 (500 nM) for 1 hour, followed by growth medium (containing 10% serum) stimulation for 24 hours.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2016 Nov 4;291(45):23756-23768. [Abstract]

BET inhibition blocks growth of TNBC cells without consistently downregulating MYC. Western blot analysis of MYC expression levels in TNBC cell lines treated for 24 hours with vehicle or 500 nM JQ1. Values on the western blot are relative to the vehicle-treated 1143 sample following normalization to β-actin.

(+)-JQ-1 purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2017 Aug;118(8):2182-2192. [Abstract]

JQ1 induces G0/G1 cell cycle arrest and apoptosis of chondrosarcoma cells via regulating p21, p27, Cyclin E2, and Cyclin D1 expression. (A and B) JQ1 regulates the expression of cell cycle regulators such as p21, p27, Cyclin E2, and Cyclin D1. SW 1353 and Hs 819.T cells are seeded into a 6-well plate for 72 h, then the cells are treated with different concentrations of JQ1 (JQ1#1: 200 nM; JQ1#2: 2 μM; JQ1#3: 20 μM) for another 24 h. Total cell lysate is used for the analysis of protein expressio